Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients. [PDF]
Pharmacol Res Perspect, 2018 Recent studies have shown that the cytochrome P450 (CYP) 3A phenotype marker 4β‐hydroxycholesterol/cholesterol (4βOHC/C) ratio is negatively correlated with body weight in healthy volunteers, and that obese patients have lower 4βOHC levels than healthy ...
Hole K +5 more
europepmc +2 more sources
PHENOTYPING CYP3A4/5 USING AN ENDOGENOUS BIOMARKER IN CHILDREN WITH DOWN SYNDROME [PDF]
Bulletin of Pharmaceutical Sciences. Assiut University, 2020 Background: Down syndrome (DS); a common chromosomal abnormality in humans can affect multiple organ systems. DS individuals usually use a wide range of medications.
Lateef Khan +5 more
doaj +1 more source
Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. [PDF]
Eur J Clin Pharmacol, 2022 PURPOSE: Variability in cytochrome P450 3A4 (CYP3A4) metabolism is mainly caused by non-genetic factors, hence providing a need for accurate phenotype biomarkers.
Eide Kvitne K +18 more
europepmc +2 more sources
Journal of Lipid Research, 2022 4β-Hydroxycholesterol (4β-OHC) is formed by Cytochrome P450 (CYP)3A and has drawn attention as an endogenous phenotyping probe for CYP3A activity. However, 4β-OHC is also increased by cholesterol autooxidation occurring in vitro due to dysregulated ...
Yosuke Suzuki +10 more
doaj +1 more source
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. [PDF]
Br J Clin Pharmacol, 2017 The CYP3A metric 4β-hydroxycholesterol (4βOHC) has been shown to correlate with tacrolimus steady-state apparent oral clearance (CL/F). Recently, pretransplant 4βOHC was shown not to predict tacrolimus CL/F after transplantation in a cohort of renal ...
Vanhove T +4 more
europepmc +2 more sources
4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? [PDF]
Br J Clin Pharmacol, 2016 There is extensive interindividual variability in drug response and tolerability. One of the major reasons for this is differences in drug metabolism, which may reflect pharmacogenetic variability and/or environmental factors, such as age and drug-drug ...
Gjestad C +3 more
europepmc +2 more sources
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. [PDF]
Br J Clin Pharmacol, 2017 Aims: Tacrolimus is a cornerstone in modern immunosuppressive therapy after kidney transplantation. Tacrolimus dosing is challenged by considerable pharmacokinetic variability, both between patients and over time after transplantation, partly due to ...
Størset E +5 more
europepmc +2 more sources
Identification and in vivo detection of side-chain hydroxylated metabolites of 4β-hydroxycholesterol
, 2023 Oxysterols are oxidized derivatives of cholesterol that are formed by enzymatic processes or through the action of reactive oxygen species. Several of these bioactive lipids have been shown to be affected and/or play a role in inflammatory processes.
Roumain, Martin +9 more
core +1 more source
Quantitative analysis of 4β- and 4α‑hydroxycholesterol in human plasma and serum by UHPLC/ESI-HR-MS [PDF]
, 2020 Cholesterol oxidation product 4β‑hydroxycholesterol (4β‑OHC) may possibly be used as an endogenous biomarker of CYP3A enzyme activity and as CYP3A4 is involved in the metabolism of approximately 50% of the drugs in clinical use, the monitoring of CYP3A ...
Turpeinen, Miia +4 more
core +1 more source
Journal of Lipid Research, 2002 Oxysterols possess powerful biological activities. Some of their effects on the regulation of key enzymes are similar to those of cholesterol, but are much more potent.
Steve Meaney +3 more
doaj +1 more source